Pathway2Targets: an open-source pathway-based approach to repurpose therapeutic drugs and prioritize human targets.
Mauri Dobbs SpendloveTrenton M GibsonShaney McCainBenjamin C StoneTristan GillBrett E PickettPublished in: PeerJ (2023)
-value < 0.025) that included EGFR, VEGFA, and PTGS2. Interestingly, there was no statistically significant enrichment of targets for other cancers in this same list suggesting high specificity of the results. We also adjusted the weighting scheme to prioritize more novel targets for CRC. This second analysis revealed epidermal growth factor receptor (EGFR), phosphoinositide-3-kinase (PI3K), and two mitogen-activated protein kinases (MAPK14 and MAPK3). These observations suggest that our open-source method with a customizable weighting scheme can accurately prioritize targets that are specific and relevant to the disease or condition of interest, as well as targets that are at earlier stages of development. We anticipate that this method will complement other approaches to repurpose drugs for a variety of indications, which can contribute to the improvement of the quality of life and overall health of such patients.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- small cell lung cancer
- end stage renal disease
- signaling pathway
- advanced non small cell lung cancer
- healthcare
- chronic kidney disease
- endothelial cells
- oxidative stress
- ejection fraction
- newly diagnosed
- prognostic factors
- climate change
- pi k akt
- health information
- patient reported outcomes
- human health
- induced pluripotent stem cells
- structural basis